Culture method of mesenchymal stem cells
By using bispecific antibodies of CD142 and SDF-1α in mesenchymal stem cell culture, the problem of insufficient vascular safety and chemotaxis of cells is solved, the safety and migration ability of cells are improved, and its in-treatment ability is enhanced, and its in-treatment ability is enhanced. effectiveness.
Patent Information
- Application Number
- CN202411447104.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-22
AI Technical Summary
In clinical applications, mesenchymal stem cells face problems such as vascular safety, cell aging and insufficient chemotaxis, resulting in risk of thrombosis, decreased function and limited therapeutic effects.
By adding bispecific antibodies of CD142 and SDF-1α to mesenchymal stem cell culture, the hemocompatibility and chemotaxis of cells are regulated, the risk of intravascular aggregation is reduced, and the cell migration ability and safety is improved.
It significantly reduces the risk of intravascular aggregation of mesenchymal stem cells, improves the safety and migration ability of cells, and enhances its effectiveness and safety in treatment.
Smart Images

Figure CN118995595A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for culturing mesenchymal stem cells, and belongs to the technical field of culturing mesenchymal stem cells. Background Art
[0002] Mesenchymal stem cells (MSCs) show great potential in regenerative medicine and tissue engineering due to their multipotency, self-renewal ability and low immunogenicity. However, despite the significant progress made in preclinical research, MSCs still face some challenges and problems in clinical application. The following discusses the clinical use of MSCs from the aspects of vascular safety, cell senescence and insufficient chemotaxis.
[0003] Vascular safety is an important consideration in the clinical application of MSCs. Because MSCs may be delivered through the vascular system, their vascular compatibility and potential thrombotic risk need to be carefully evaluated. Blood compatibility refers to the interaction between MSCs and blood cells that may affect the safety of stem cells in blood vessels. Thrombotic risk means that in some cases, MSCs may affect blood fluidity or coagulation processes, increasing the risk of thrombosis. This is particularly important when MSCs are delivered via the intravenous route. Although MSCs have low immunogenicity, they may still stimulate immune responses in some patients, leading to vascular inflammation or damage. After intravenous infusion of MSCs, there are reports that patients may develop serious complications such as pulmonary embolism. For example, Jung et al. reported acute chest pain and multiple pulmonary emboli in patients with cervical disc herniation treated with intravenous infusion of adipose-derived MSCs three times, suggesting that MSCs infusion may cause thrombosis.
[0004] With the extension of culture time or the increase of in vitro expansion times, MSCs may experience aging, which can significantly affect their function and therapeutic effects. For example, the proliferation capacity decreases. Aged MSCs show a slowed proliferation rate, which limits their use in large-scale therapeutic applications. Reduced differentiation potential. Aging may affect the multidirectional differentiation potential of MSCs and reduce their effectiveness in tissue repair and regeneration. Paracrine function changes. The paracrine function of MSCs, including the secretion of growth factors and cytokines, may change due to aging, affecting its ability to promote tissue repair. In addition, with cell aging, the risk of gene mutation increases, which may affect the safety and function of MSCs.
[0005] The homing ability of MSCs, that is, their ability to migrate to sites of injury or disease, is a key factor in their therapeutic efficacy. However, the natural chemotactic ability of MSCs may not be sufficient to achieve optimal therapeutic effects. MSCs may not migrate to target tissues efficiently, resulting in limited therapeutic effects. MSCs may not express sufficient chemokine receptors, limiting their response to injury signals. In addition, MSCs may not be able to adapt to the complex pathological microenvironment, affecting their survival and function.
[0006] Therefore, exploring and studying the culture methods of mesenchymal stem cells in order to enhance certain characteristics or capabilities of mesenchymal stem cells and "empower" them is a current research hotspot.
[0007] Bispecific antibodies (bsAbs) are a special type of antibody that can simultaneously recognize and bind to two different antigenic epitopes or two different epitopes on the same antigen. The design of this antibody gives it unique advantages in therapeutic applications, especially in the field of tumor immunotherapy. Bispecific antibodies can bind to two different molecules at the same time, which enables them to guide effector cells (such as T cells or NK cells) to tumor cells, thereby enhancing the immune response. Summary of the invention
[0008] In view of the above-mentioned prior art, the present invention provides a method for culturing mesenchymal stem cells. The mesenchymal stem cells cultured by the present invention have low risk of intravascular aggregation, high safety and strong migration ability.
[0009] The present invention is achieved through the following technical solutions: A method for culturing mesenchymal stem cells is as follows: when culturing the mesenchymal stem cells, a bispecific antibody of CD142 and SDF-1α is added.
[0010] Furthermore, the mesenchymal stem cells are primary mesenchymal stem cells that have been passaged and expanded.
[0011] Furthermore, the concentration of the bispecific antibody of CD142 and SDF-1α is 100 ng / ml.
[0012] Furthermore, after adding the bispecific antibody of CD142 and SDF-1α, the cells were routinely cultured at 37°C and 5% CO2 for 24 h or until the cell density reached 30,000 to 50,000 cells / cm 2 When the cells were grown, they were collected and frozen.
[0013] Furthermore, when the cells grow to a suitable density, the cells are digested, collected and washed, cryoprotectants are added for cryopreservation, the cells are cooled in a programmed cooling box, and finally stored in a liquid nitrogen tank.
[0014] Furthermore, the mesenchymal stem cells are mesenchymal stem cells derived from umbilical cord.
[0015] The mesenchymal stem cells cultured using the above method have low risk of intravascular aggregation, high safety, and strong migration ability.
[0016] The present invention uses a bispecific antibody of CD142 and SDF-1α to treat mesenchymal stem cells to improve the safety and migration ability of mesenchymal stem cells. The principle is as follows: (1) CD142, also known as tissue factor (TF), is a membrane-bound glycoprotein that plays a key role in the blood coagulation process. In MSCs, the expression of CD142 is of great significance for blood compatibility. According to studies, human umbilical cord mesenchymal stem cells (UC-MSCs) accelerate the coagulation of platelet plasma by expressing CD142. This acceleration is achieved by initiating the coagulation process by forming a complex between CD142 and coagulation factor VII or VIIa. In addition, studies have found that the expression of CD142 in UC-MSCs increases with the increase in cell generations, indicating that its upregulation is the result of UC-MSCs autocrine secretion, and CD142 can affect the chemotaxis and colonization ability of UC-MSCs. These findings suggest that CD142 not only plays a role in UC-MSCs promoting blood coagulation, but may also have an important impact on the migration and tissue repair ability of stem cells in vivo. The present invention regulates mesenchymal stem cells or even inhibits the expression or function of CD142 through CD142 antibodies, which helps to improve the safety and effectiveness of MSCs treatment, especially in situations where blood compatibility is required, such as through arterial intervention or intravenous infusion treatment or in application scenarios of contact with other blood components.
[0017] (2) CXCR4 is a G protein-coupled receptor that is widely expressed in a variety of cell types and plays an important role in cell migration, differentiation and tissue repair. In MSCs, CXCR4 is mainly involved in cell migration and homing. As a receptor for stromal cell-derived factor-1 (SDF-1), CXCR4 mediates the migration and homing of MSCs to sites of injury or inflammation through the SDF-1 / CXCR4 axis. This process is crucial for the effectiveness of MSCs in tissue repair and immunoregulation. CXCR4 plays a role in the immunoregulatory function of MSCs, affecting the interaction between MSCs and immune cells, which may in turn regulate inflammatory responses and promote tissue healing. During MSC transplantation, various strategies to enhance the SDF-1 / CXCR4 interaction, such as combining chemokines, cytokines, hormones, drugs, biomaterials, genetic engineering and hypoxic conditions, can improve the therapeutic effect of MSCs. SDF-1 is the only ligand for CXCR4 and is mainly secreted by bone marrow stromal cells. When the body is damaged, the concentration of SDF-1 at the damaged site increases, forming a concentration gradient that attracts MSCs expressing CXCR4 to migrate to the damaged site and participate in the repair process.
[0018] (3) In the present invention, mesenchymal stem cells expressing CD142 and chemokine SDF-1 are coupled through two antigen recognition epitopes of the bispecific antibody, which can enhance the chemotactic ability of mesenchymal stem cells and help solve the bottleneck problems of cell transplantation mode, cell homing and small number of cell colonization in stem cell therapy. At the same time, by blocking the tissue factor CD142, the blood safety of mesenchymal stem cells is improved.
[0019] Various terms and phrases used herein have the general meanings that are well known to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : Photographs of mesenchymal stem cells at passage P3 (100×).
[0021] Figure 2 : Schematic diagram of CD142 flow cytometry expression results, where A is the blank control group, B is the experimental group, and C is the control group.
[0022] Figure 3 : Photos of migrating cells (100×), where A is the control group and B is the experimental group.
[0023] Figure 4 : Photos of plasma from each treatment group, where from left to right are blank group, experimental group, and control group. DETAILED DESCRIPTION
[0024] The present invention will be further described below in conjunction with the embodiments. However, the scope of the present invention is not limited to the following embodiments. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.
[0025] The instruments, reagents, materials, etc. involved in the following embodiments, unless otherwise specified, are all conventional instruments, reagents, materials, etc. in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following embodiments, unless otherwise specified, are all conventional experimental methods, detection methods, etc. in the prior art.
[0026] The bispecific antibody of CD142 and SDF-1α used in the present invention is prepared by conventional methods and is prepared by a third party commissioned by the applicant.
[0027] The complete culture medium used in the present invention is a MSC stem cell serum-free basal culture medium (BI, catalog number: 05-200-1A) supplemented with 2% Uitroser™ G serum substitute (PALL, catalog number: 15950).
[0028] The mouse CD142 FITC-coupled antibody working solution (abcam, catalog number: ab228968) used in the present invention is a fluorescently labeled antibody used for stem cell surface labeling in the prior art.
[0029] Example 1 Cultivation of mesenchymal stem cells 1. Isolation and Culture of Umbilical Cord Mesenchymal Stem Cells Umbilical cord tissue was obtained from donations from pregnant women who underwent cesarean section (with ethical review and informed consent from donors). The tissue was placed in a sterile centrifuge tube and quickly transferred to a biosafety cabinet at 2-8°C. The umbilical cord tissue was transferred to a 100 mm culture dish with sterile tweezers, and an equal amount of PBS containing antibiotics was added for repeated washing to remove blood components. The umbilical artery and vein were stripped, the Wharton's jelly was cut into pieces, and saline was added for washing and centrifugation. The upper layer of liquid was discarded, the tissue was resuspended in PBS, filtered, centrifuged, the supernatant was discarded, and the tissue blocks were retained for primary adherent culture. The tissue blocks were resuspended in complete medium, inoculated in a T75 culture flask, and cultured in a cell culture incubator at 37°C, 5% C02, 5% O2, and high saturated humidity.
[0030] Experimental group: When the primary confluence reached more than 80% (primary cell P0), subculture was performed until P3, and then bispecific antibodies of CD142 and SDF-1α (100 ng / ml) were added. The cells were routinely cultured at 37°C and 5% CO2 for 24 h, and then harvested and cryopreserved to obtain working cells. The photo of P3 mesenchymal stem cells is shown in Figure 2. Figure 1 shown.
[0031] Control group: When the primary confluence reached more than 80% (primary cell P0), subculture was performed, and the subculture was continued until P3, when the seed cells were harvested and frozen.
[0032] Blank control group: peripheral blood mononuclear cells.
[0033] 2. Identification of UCMSCs Surface Markers by Flow Cytometry According to the above grouping (experimental group, control group, blank control group), the third generation cells in the logarithmic growth phase were taken and prepared into a concentration of 1×10 6 / ml cell suspension. Add 100μl of single cell suspension to each sample tube, centrifuge, add 2μl of mouse CD142 FITC-conjugated antibody working solution to each tube, incubate in the dark, wash with PBS, and resuspend the cells. Use software to analyze the positive expression rate of MSC-specific surface marker CD142 on a SONY SA3800 flow cytometer.
[0034] The results of CD142 flow cytometry expression were as follows: Figure 2 As shown, it can be seen that the expression rate of CD142 decreased from 82.97% before blocking to 1.87% after bispecific antibody blocking.
[0035] 3. Transwell assay to assess migration ability The MSCs from the experimental group and the control group were collected and the cell concentration was adjusted to an appropriate density (1×10 5 cells / mL). Add the cell suspension to the upper chamber of the Transwell chamber, and add 150μl of cell suspension to each chamber. Add 100 ng / ml SDF-1α to the culture medium in the lower chamber. Place the entire system in a cell culture incubator and culture at 37°C and 5% CO2 for 24 hours.
[0036] After the culture is completed, remove the Transwell chamber and gently rinse with PBS to remove the non-migrated cells. Use a cotton swab to remove the cells in the upper chamber of the chamber. Use a fixative (4% paraformaldehyde) to fix the cells that have migrated to the lower side of the chamber. Stain the cells with crystal violet dye for observation and counting. Remove the cells from the lower side of the Transwell chamber and observe and count the number of migrated cells directly under a microscope. Select three fields of view, count the cells, and calculate the migration index: Migration index = number of migrated cells in the experimental group (mean) / number of migrated cells in the control group (mean).
[0037] Photographs of migrating cells Figure 3 As shown, the migration index of the experimental group was 2.06, indicating that the migration ability of the mesenchymal stem cells in the experimental group treated with the bispecific antibody was significantly enhanced.
[0038] 4. Coagulation test After signing the informed consent form, adult plasma was collected by medical staff, and the blood was stored and transported in sodium heparin anticoagulant tubes and processed within 6 hours. The blood was first centrifuged at 1200 r / min and the upper plasma was taken to obtain the plasma containing platelets. The plasma was aliquoted and stored at -20°C for later use.
[0039] According to the grouping in 1 above (experimental group, control group, blank control group), the third generation cells in the logarithmic growth phase were taken to prepare a cell suspension, which was washed once with PBS buffer without calcium and magnesium ions, centrifuged, and the precipitate was resuspended with 1 mL of platelet-containing plasma. The cell density was adjusted to 5.0×10 6 / ml (placed in a 1.5 mL EP tube). Then add 50 μl of CaCl2 solution for injection, mix immediately by blowing, place at room temperature and start timing. During the timing process, invert the EP tube every 10 seconds to observe whether the plasma refluxes, and record the complete coagulation time of the plasma. The timing end point is when the plasma fails to reflux when the EP tube is inverted.
[0040] At 50 s, the plasma of each treatment group is shown in the figure below. Figure 4 As shown, it can be seen that the experimental group did not coagulate, while the control group and the blank group did coagulate, indicating that the present invention can reduce the aggregation of mesenchymal stem cells through the treatment of bispecific antibodies and improve the safety of application.
[0041] The above examples are provided to those skilled in the art to fully disclose and describe how to make and use the claimed embodiments, and are not intended to limit the scope of the disclosure herein. Modifications that are obvious to those skilled in the art will fall within the scope of the appended claims.
Claims
1. A method for culturing mesenchymal stem cells, characterized in that: When culturing mesenchymal stem cells, a bispecific antibody of CD142 and SDF-1α is added.
2. The method for culturing mesenchymal stem cells according to claim 1, characterized in that: The mesenchymal stem cells are primary mesenchymal stem cells that have been passaged and expanded.
3. The method for culturing mesenchymal stem cells according to claim 1, characterized in that: The concentration of the bispecific antibody of CD142 and SDF-1α was 100 ng / ml.
4. The method for culturing mesenchymal stem cells according to claim 1, characterized in that: After adding the bispecific antibody of CD142 and SDF-1α, the cells were cultured at 37° C. and 5% CO 2 .
5. The method for culturing mesenchymal stem cells according to claim 1, characterized in that: The mesenchymal stem cells are mesenchymal stem cells derived from umbilical cord.
